TABLE 1

New therapeutic options

DrugPreclinicalPhase IPhase IIPhase IIIFDA approved
Siderophore cephalosporins
    Cefiderocol-
    Others
        GSK-3342830-a---
        Fimsbactin plus daptomycin----
        GT-1----
Tetracyclines
    Eravacycline
    TP-6076---
New non-β-lactam–β-lactamase inhibitors paired with existing β-lactam antibiotics
    ETX2514 plus sulbactam--
    WCK 4234 plus meropenem (WCK-5999)----
    LN-1-255 plus meropenem-imipenem----
    VNRX-5113 (partner β-lactam unspecified)---
    WCK 5153 plus sulbactam----
    Zidebactam plus cefepime---
New β-lactam antibiotics
    AIC-499 (partner β-lactam inhibitor unspecified)---
    FSI-1671 plus sulbactam---
Polymyxin B-derived molecules
    SPR741---
    FADDI-287----
Aminoglycosides
    Apramycin----
Other drug candidates
    LpxC inhibitors----
    RX-P873----
Other therapeutic options
    Bacteriophage therapy-
    Monoclonal antibodies
        C8----
        AR-401----
  • a -, terminated and under review.